AACC uses cookies to ensure the best website experience. Continuing without changing cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy


With both nonalcoholic fatty liver disease and the next, more aggressive stage—nonalcoholic steatohepatitis both on the rise worldwide a vibrant research effort is underway to find robust noninvasive biomarkers to identify and stage these conditions.

Ask the Expert

Bench Matters

Federal Insider

Focus on Mass Spectrometry

One of the motivations to bring mass spectrometry assays in-house is to reduce send out costs. But sometimes there is limited financial return on a cost per reportable basis unless leaders take a wider view of patient care.

Industry Playbook

Regulatory Roundup

The Sample